**Please submit your abstract by filling in this form and send it to the secretariat**

**<asia@ajlgks2023.com > by email by ~~October 7, 2022.~~ → October 31, 2022.**

**Please send the entire form including page 2, the sample, although we will use the information you enter in pages 1 and 3 only.**

**Please enter the information on the Presenting Author (Contact Person) below.**

Name:

Affiliation:

Title (Prof. / Dr. / Mr. / Ms.):

Address:

Telephone:

Email address:

**Please select one (type X above the bar) for each of the following items:**

**1. For which do you want to submit your abstract, Symposium or General Session?**

 Symposium General Session

**2. If you select Symposium, please select ONLY ONE category for your abstract from the following symposium categories:**

**Symposium Categories:**

 1. Long term results of Gamma Knife radiosurgery for benign lesion －efficacy and complication.

 2. SRT for metastatic brain tumors －optimal number of fraction and dose.

 3. Gamma Knife radiosurgery for large AVM

**3. Please select ONLY ONE category for your abstract from the following general session categories:**

**General Session Categories:**

 1. Vascular disorders

 2. Benign tumors

 3. Metastases

 4. Malignant Tumors (except metastases)

 5. Functional disorders

 6. Diagnostic techniques (imaging)

 7. Dose planning techniques

 8. Physics, QA, QC

 9. Nursing

 10. Others

**4. Please select ONLY ONE category for your presentation:**

**Note: Japanese participants are limited to on-site presentation**

 On-site presentation Web presentation (Online)

**Please enter your Abstract Title, Name of Author(s), Affiliation(s) of Author(s) and Abstract Text in English using Times New Roman font within each column in the page 3 according to the instruction below.**

|  |  |
| --- | --- |
| Abstract Title | Type **in bold** using **Times New Roman 11-Point** font. |
| Name of Author(s) | Use **Times New Roman** **10-Point** font. Place affiliation number(s) with superscripts. |
| Affiliation(s) of Author(s) |
| Abstract Text | Type **within 350 words** using **Times New Roman** **10-Point** font. |

Please note in advance that **submitted abstract will be printed in the abstract book as you enter in the page 3 of this form.**

Please refer to the SAMPLE on page 2 when you enter your abstract.

**SAMPLE**

**\*Please follow this sample when you enter your abstract in the page 3 of this form. The frame will not be shown when we print your abstract in the abstract book.**

Please enter your Abstract Text in the 4th column. Type in **English** **within 350 words** using **Times New Roman** **10-Point** font

|  |
| --- |
| **Early effect of stereotactic radiotherapy for large metastatic brain tumors –Comparison between the gamma knife and Novalis STx linear accelerator**Please enter your Abstract Title in the 1st column.Type the title **in bold in 11-Point**. |
| Takashi Shuto1), Shigeo Matsunaga2)Please enter Name of Author(s) in the 2nd column. |
| 1) Department of Neurosurgery, Yokohama Rosai Hospital2) Stereotactic Radiotherapy Center, Yokohama Rosai HospitalPlease enter Affiliation(s) of Author(s) in the 3rd column. |
| **Introduction** For large metastatic brain tumors (>8 cc), we mainly use 40 Gy/10-fraction stereotactic radiotherapy (SRT) using Novalis STx linear accelerator (Novalis STx) to reduce the risk of radiation damage. For patients in poor condition, we often use 35Gy/5 fraction SRT using gamma knife (GK) to shorten the treatment period. We examined the change in tumor volume at the end of irradiation as an early treatment effect and differences between GK and Novalis STx techniques.**Methods** The Novalis group consisted of 51 patients (20 men and 31 women) with 58 lesions; their tumor volume was calculated at the beginning and end of 10 SRT sessions. Primary cancer was located in the lung in 21 patients, the breast in 13, and other locations in 17. Tumor volume of 25 lesions was calculated after administration of five fractions. In addition, 10 lesions treated with GK using 35Gy/5 fractions were examined, and the tumor volume was calculated at the beginning and end of irradiation. Treatment using Novalis STx used a dynamic conformal arc with an intensity-modulated radiation therapy beam; therefore, the dose distribution was homogenous, in contrast to the dose distribution with GK.**Results** The average interval between pretreatment MRI and the end of irradiation was 17 days. The median pretreatment volume of the 58 lesions treated using Novalis STx was 11.6 cc, and 9.5 cc at the end of 10 fractions of SRT (*p* < 0.0001). However, the difference in tumor volume between pretreatment and midpoint (five fractions) was not significant. The median pretreatment volume of 10 lesions treated using GK was 11.9 cc, and 11.0 cc at the end of five fractions of SRT (*p* < 0.04).**Conclusions** Ten fractions of SRT using Novalis STx for large metastatic brain tumor, significantly decreased the tumor volume at the end of irradiation, but the change was not significant after the 5th irradiation. Conversely, five fractions of SRT using GK significantly decreased the tumor volume at the end of irradiation. We recommend re-imaging and consideration of re-planning at the midpoint (five fractions) in 10 fractions of SRT using GK. |

|  |
| --- |
|  |
|  |
|  |
|  |